Theranos' Valuation, Martin Shkreli's Fiduciary Responsibility, And Can Pfizer's Tax Inversion Save U.S. Pharma? [Video]

Every year at our annual Forbes Healthcare Summit, I feel like I cram a month's worth of reporting into a day-and-a-half. Many Forbes writes have already weighed in, as have outside organizations like Bloomberg, Gawker, and Business Insider. I'm still recovering and formulating my own thoughts. But for all of you who couldn't be there, here are the first video clips from the day. Keep in mind: these are just snapshots of what was a 10-hour-plus discussion about cost, value, data openness, and innovation. There will be more video from the day, and I'll have more to say. But here are some amazing moments.